Dec 15, 2025
Gilead’s Experimental Combo Tablet For HIV Treatment Hits Primary Goal

Gilead Sciences Inc. (NASDAQ:GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial. The trial evaluated the treatment responses of adults with HIV who are virologically suppressed, switching from Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF) to a fixed-dose combination of…

Dec 15, 2025
Why Is Immunome Stock Soaring Monday?

Immunome Inc. (NASDAQ:IMNM) stock rose Monday, with session volume surging to 8.25 million shares, well above the stock’s average daily volume of 1.50 million, according to Benzinga Pro data. Immunome on Monday shared topline results from the global pivotal Phase…

Dec 15, 2025
What’s Driving The Sell-Off In Luminar Technologies (LAZR) Stock?

Luminar Technologies, Inc. (NASDAQ:LAZR) shares are under heavy pressure Monday after the company announced that it initiated voluntary Chapter 11 proceedings to pursue court-supervised sale processes for its core businesses. Luminar Technologies shares are approaching critical lows. What’s pressuring LAZR? What To Know:…

Dec 15, 2025
Why Is Radiopharm Theranostics Stock Rallying Over 140%?

Radiopharm Theranostics Limited (NASDAQ:RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro. On Monday, Radiopharm Theranostics shared interim data from the…

Dec 15, 2025
CrowdStrike Says AI Prompts Are The New Malware

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) on Monday announced the general availability of Falcon AI Detection and Response (AIDR), expanding its Falcon platform to address what the company describes as the fastest-growing AI attack surface: the AI prompt and agent interaction layer.…

Dec 15, 2025
Palvella: 73% Improved In Phase 2 Study Of Skin Condition Treatment

Palvella Therapeutics, Inc. (NASDAQ:PVLA) on Monday shared topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for cutaneous venous malformations (cutaneous VMs). Cutaneous venous malformations are common, benign, slow-flow vascular anomalies appearing as…

Dec 15, 2025
Canopy Growth To Acquire MTL Cannabis

Canopy Growth Corporation (NASDAQ:CGC) has agreed to acquire MTL Cannabis Corp. (OTCQX:MTLNF) in a cash-and-stock transaction valued at approximately 125 million Canadian dollars on a fully diluted equity basis, or about 179 million Canadian dollars on an enterprise value basis.…